Date: 2014-08-14
Type of information: Collaboration agreement
Compound: ConfirmMDx® for Prostate Cancer
Company: MDxHealth (Belgium) Ancillary Care Services (USA - TX)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration agreement
Action mechanism: ConfirmMDx for Prostate Cancer is an epigenetic assay to help urologists distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test is able to detect an epigenetic field effect or \"halo\" associated with the cancerization process at the DNA level. This molecular \"halo\" around a cancer lesion can be present despite having a normal appearance under the microscope. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and rule in high-risk patients who may require repeat biopsies and potential treatment. Performance of the proprietary ConfirmMDx genes and technology has been published in 42 studies with over 4,100 patients tested.
Disease: prostate cancer
Details: * On August 14, 2014, MDxHealth, a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced that it has signed agreements with Ancillary Care Services (ACS), a subsidiary of American CareSource Holdings Inc. ACS offers its providers quality and cost-effective healthcare services through their managed care network agreements covering 4.5 million lives. The agreement provides patients access to MDxHealth\'s ConfirmMDx® for Prostate Cancer test.
The addition of this agreement to MDxHealth\'s current contracted network raises coverage access to the ConfirmMDx for Prostate Cancer testing to over 152 million covered lives throughout the U.S. MDxHealth continues to ensure coverage and reimbursement contracting with PPO, commercial payors and other specialized networks.
Financial terms:
Latest news:
